



Clinical trial results:

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes

Summary

EudraCT number	2013-000239-28
Trial protocol	GB CZ IT SE SK BG NL ES DE PL HU BE
Global end of trial date	16 September 2018

Results information

Result version number	v1 (current)
This version publication date	25 September 2019
First version publication date	25 September 2019

Trial information

Trial identification

Sponsor protocol code	D1693C00001
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01730534
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AstraZeneca AB
Sponsor organisation address	151 85, Södertälje, Sweden,
Public contact	Information Centre, AstraZeneca AB, +1 800 2369933, information.centre@astrazeneca.com
Scientific contact	Global Study Leader, AstraZeneca, +49 4103 708 3792, Sandra.ranft@astrazeneca.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 September 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	11 September 2018
Global end of trial reached?	Yes
Global end of trial date	16 September 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective is to determine the effect of dapagliflozin relative to placebo on cardiovascular outcome when added to current background therapy in patients with type 2 diabetes mellitus (T2DM) with either established cardiovascular disease or at least two cardiovascular risk factors.

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 April 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 326
Country: Number of subjects enrolled	Mexico: 868
Country: Number of subjects enrolled	Australia: 414
Country: Number of subjects enrolled	China: 215
Country: Number of subjects enrolled	Hong Kong: 50
Country: Number of subjects enrolled	India: 193
Country: Number of subjects enrolled	Japan: 95
Country: Number of subjects enrolled	Philippines: 336
Country: Number of subjects enrolled	Korea, Republic of: 357
Country: Number of subjects enrolled	Taiwan: 110
Country: Number of subjects enrolled	Argentina: 683
Country: Number of subjects enrolled	Thailand: 259
Country: Number of subjects enrolled	Vietnam: 157
Country: Number of subjects enrolled	Belgium: 114
Country: Number of subjects enrolled	Bulgaria: 832
Country: Number of subjects enrolled	Czech Republic: 638
Country: Number of subjects enrolled	France: 187
Country: Number of subjects enrolled	Germany: 215
Country: Number of subjects enrolled	Hungary: 713
Country: Number of subjects enrolled	Israel: 340
Country: Number of subjects enrolled	Italy: 155

Country: Number of subjects enrolled	Netherlands: 401
Country: Number of subjects enrolled	Poland: 931
Country: Number of subjects enrolled	Romania: 483
Country: Number of subjects enrolled	Russian Federation: 395
Country: Number of subjects enrolled	Slovakia: 346
Country: Number of subjects enrolled	South Africa: 456
Country: Number of subjects enrolled	Spain: 195
Country: Number of subjects enrolled	Sweden: 453
Country: Number of subjects enrolled	Turkey: 53
Country: Number of subjects enrolled	Ukraine: 356
Country: Number of subjects enrolled	United Kingdom: 366
Country: Number of subjects enrolled	Canada: 1583
Country: Number of subjects enrolled	United States: 3885
Worldwide total number of subjects	17160
EEA total number of subjects	6029

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	9253
From 65 to 84 years	7890
85 years and over	17

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

In DECLARE at the first visit, i.e. the enrollment visit 1, patients were evaluated regarding the protocol mandated inclusion and exclusion criteria. If eligible, the patient started a single-blind (for the patient) run-in period receiving placebo tablets for 4-8 weeks.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Dapa 10 mg

Arm description:

Dapagliflozin 10 mg tablets administered orally once daily

Arm type	Active comparator
Investigational medicinal product name	Dapagliflozin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Dapagliflozin 10 mg tablets administered orally once daily

Arm title	Placebo
------------------	---------

Arm description:

Matching placebo for dapagliflozin 10 mg administered orally once daily

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Matching placebo for dapagliflozin 10 mg administered orally once daily

Number of subjects in period 1	Dapa 10 mg	Placebo
Started	8582	8578
Completed	8473	8433
Not completed	109	145
Consent withdrawn by subject	97	127
Lost to follow-up	12	18

Baseline characteristics

Reporting groups

Reporting group title	Dapa 10 mg
Reporting group description: Dapagliflozin 10 mg tablets administered orally once daily	
Reporting group title	Placebo
Reporting group description: Matching placebo for dapagliflozin 10 mg administered orally once daily	

Reporting group values	Dapa 10 mg	Placebo	Total
Number of subjects	8582	8578	17160
Age, Customized Units: Subjects			
<65 years	4631	4622	9253
≥65 years	3951	3956	7907
Age Continuous Units: years			
arithmetic mean	63.9	64.0	
standard deviation	± 6.8	± 6.8	-
Sex: Female, Male Units: Subjects			
Male	5411	5327	10738
Female	3171	3251	6422
Race/Ethnicity, Customized Units: Subjects			
White	6843	6810	13653
Black or African American	295	308	603
Asian	1148	1155	2303
American Indian or Alaska Native	52	52	104
Native Hawaiian or other Pacific Islander	9	13	22
Other	235	240	475
Age, Customized Units: Subjects			
<75 years	8044	8020	16064
≥75 years	538	558	1096
Baseline CV risk category Units: Subjects			
Established CV disease	3474	3500	6974
Multiple risk factors for CV events	5108	5078	10186
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	1298	1270	2568
Not Hispanic or Latino	7284	7308	14592
Unknown or Not Reported	0	0	0

End points

End points reporting groups

Reporting group title	Dapa 10 mg
Reporting group description: Dapagliflozin 10 mg tablets administered orally once daily	
Reporting group title	Placebo
Reporting group description: Matching placebo for dapagliflozin 10 mg administered orally once daily	

Primary: Time to first event included in the composite endpoint of CV death, MI or ischemic stroke

End point title	Time to first event included in the composite endpoint of CV death, MI or ischemic stroke
End point description: Safety and co-primary efficacy	
End point type	Primary
End point timeframe: up to 5.2 years	

End point values	Dapa 10 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8582	8578		
Units: Participants				
Number of patients with an event	756	803		

Statistical analyses

Statistical analysis title	Cox regression
Comparison groups	Dapa 10 mg v Placebo
Number of subjects included in analysis	17160
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.172
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	1.03

Primary: Time to first event included in the composite endpoint of CV death or hospitalization due to heart failure.

End point title	Time to first event included in the composite endpoint of CV death or hospitalization due to heart failure.
-----------------	---

End point description:

Co-primary efficacy

End point type	Primary
----------------	---------

End point timeframe:

up to 5.2 years

End point values	Dapa 10 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8582	8578		
Units: Participants				
Number of patients with an event	417	496		

Statistical analyses

Statistical analysis title	Cox regression
Comparison groups	Dapa 10 mg v Placebo
Number of subjects included in analysis	17160
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.005
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	0.95

Secondary: Time to first event of renal composite endpoint: Confirmed sustained $\geq 40\%$ decrease in eGFR to eGFR < 60 ml/min/1.73m² and/or ESRD and/or renal or CV death.

End point title	Time to first event of renal composite endpoint: Confirmed sustained $\geq 40\%$ decrease in eGFR to eGFR < 60 ml/min/1.73m ² and/or ESRD and/or renal or CV death.
-----------------	--

End point description:

Secondary

End point type	Secondary
End point timeframe:	
up to 5.2 years	

End point values	Dapa 10 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8582	8578		
Units: Participants				
Number of patients with an event	370	480		

Statistical analyses

Statistical analysis title	Cox regression
Comparison groups	Dapa 10 mg v Placebo
Number of subjects included in analysis	17160
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.67
upper limit	0.87

Secondary: Time to All-cause mortality.

End point title	Time to All-cause mortality.
End point description:	
Secondary	
End point type	Secondary
End point timeframe:	
up to 5.2 years	

End point values	Dapa 10 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8582	8578		
Units: Participants				
Number of patients with an event	529	570		

Statistical analyses

Statistical analysis title	Cox regression
Comparison groups	Dapa 10 mg v Placebo
Number of subjects included in analysis	17160
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.198
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	1.04

Adverse events

Adverse events information

Timeframe for reporting adverse events:

up to 5.2 years

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21
--------------------	----

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Matching placebo for dapagliflozin 10 mg administered orally once daily

Reporting group title	Dapa 10 mg
-----------------------	------------

Reporting group description:

Dapagliflozin 10 mg tablets administered orally once daily

Serious adverse events	Placebo	Dapa 10 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	3418 / 8569 (39.89%)	3205 / 8574 (37.38%)	
number of deaths (all causes)	569	529	
number of deaths resulting from adverse events	566	527	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acral lentiginous melanoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myeloid leukaemia			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 2	
Acute myelomonocytic leukaemia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma			

subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma gastric			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 2	0 / 1	
Adenocarcinoma of appendix			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	18 / 8569 (0.21%)	20 / 8574 (0.23%)	
occurrences causally related to treatment / all	0 / 18	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 1	
Adenocarcinoma pancreas			
subjects affected / exposed	5 / 8569 (0.06%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 5	1 / 4	
deaths causally related to treatment / all	0 / 5	1 / 1	
Adenoid cystic carcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenoma benign			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal adenoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal neoplasm			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenocortical carcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal squamous cell carcinoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaplastic astrocytoma			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Anaplastic large-cell lymphoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	27 / 8569 (0.32%)	34 / 8574 (0.40%)	
occurrences causally related to treatment / all	0 / 37	0 / 42	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basosquamous carcinoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Benign breast neoplasm			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign ear neoplasm			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign gastric neoplasm			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign gastrointestinal neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign hepatic neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign laryngeal neoplasm			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign lung neoplasm			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign lymph node neoplasm			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of bladder			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of adrenal gland			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of thyroid gland			
subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of spinal cord			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign ovarian tumour			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign pancreatic neoplasm			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign renal neoplasm			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign salivary gland neoplasm			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign soft tissue neoplasm			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	25 / 8569 (0.29%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	3 / 25	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer recurrent			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer stage 0, with cancer in situ			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			
subjects affected / exposed	5 / 8569 (0.06%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder papilloma			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			
subjects affected / exposed	8 / 8569 (0.09%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	2 / 8	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Bladder transitional cell carcinoma metastatic			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Bone cancer			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone cancer metastatic			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bone neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bowen's disease			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain neoplasm			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Brain neoplasm benign			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain neoplasm malignant			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 0	
Breast cancer			

subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer female			
subjects affected / exposed	20 / 8569 (0.23%)	19 / 8574 (0.22%)	
occurrences causally related to treatment / all	0 / 22	2 / 20	
deaths causally related to treatment / all	0 / 1	0 / 0	
Breast cancer metastatic			
subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial carcinoma			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cancer pain			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carcinoid tumour of the duodenum			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carcinoid tumour of the small bowel			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central nervous system lymphoma			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cervix carcinoma			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			
subjects affected / exposed	7 / 8569 (0.08%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	1 / 7	0 / 5	
deaths causally related to treatment / all	0 / 3	0 / 5	
Chondromatosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondrosarcoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic leukaemia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic lymphocytic leukaemia			
subjects affected / exposed	6 / 8569 (0.07%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic myeloid leukaemia			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell renal cell carcinoma			

subjects affected / exposed	0 / 8569 (0.00%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Colon adenoma			
subjects affected / exposed	7 / 8569 (0.08%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	16 / 8569 (0.19%)	16 / 8574 (0.19%)	
occurrences causally related to treatment / all	0 / 16	0 / 17	
deaths causally related to treatment / all	0 / 2	0 / 2	
Colon cancer metastatic			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Colon neoplasm			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal adenocarcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Colorectal cancer metastatic			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dermatofibrosarcoma protuberans			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ductal adenocarcinoma of pancreas			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial adenocarcinoma			
subjects affected / exposed	7 / 8569 (0.08%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Endometrial cancer			
subjects affected / exposed	5 / 8569 (0.06%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer metastatic			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fallopian tube cancer metastatic			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Follicular thyroid cancer			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibroadenoma of breast			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder cancer metastatic			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gallbladder adenocarcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastric adenoma			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer			
subjects affected / exposed	8 / 8569 (0.09%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 1	
Gastric cancer stage 0			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal adenocarcinoma			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal carcinoma			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stromal cancer			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stromal tumour			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal tract adenoma			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingival cancer			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Glioblastoma			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma multiforme			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
Glottis carcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemangioma			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemangiopericytoma			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hairy cell leukaemia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cancer			
subjects affected / exposed	5 / 8569 (0.06%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 5	0 / 1	
Hepatic cancer metastatic			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular carcinoma			
subjects affected / exposed	4 / 8569 (0.05%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	0 / 4	0 / 9	
deaths causally related to treatment / all	0 / 2	0 / 4	
Hodgkin's disease			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypopharyngeal cancer			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Infected neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Intestinal adenocarcinoma			

subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal proliferative breast lesion			
subjects affected / exposed	2 / 8569 (0.02%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive breast carcinoma			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive ductal breast carcinoma			
subjects affected / exposed	5 / 8569 (0.06%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive lobular breast carcinoma			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Juvenile melanoma benign			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratoacanthoma			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine benign neoplasm			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer			

subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Laryngeal cancer metastatic			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Laryngeal squamous cell carcinoma			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lentigo maligna			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukaemia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Lipoma			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liposarcoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	6 / 8569 (0.07%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	1 / 7	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 1	
Lung cancer metastatic			

subjects affected / exposed	14 / 8569 (0.16%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 14	0 / 12	
deaths causally related to treatment / all	0 / 13	0 / 6	
Lung carcinoma cell type unspecified stage 0			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 2	0 / 2	
Lung neoplasm malignant			
subjects affected / exposed	21 / 8569 (0.25%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 21	0 / 13	
deaths causally related to treatment / all	0 / 4	0 / 6	
Lung squamous cell carcinoma metastatic			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 0	
Lymphocytic leukaemia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoma			
subjects affected / exposed	1 / 8569 (0.01%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	1 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant anorectal neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			

subjects affected / exposed	12 / 8569 (0.14%)	13 / 8574 (0.15%)	
occurrences causally related to treatment / all	0 / 12	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma in situ			
subjects affected / exposed	4 / 8569 (0.05%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	1 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of pleura metastatic			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant neoplasm of renal pelvis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of unknown primary site			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant peritoneal neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant pleural effusion			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melanocytic naevus			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melanoma recurrent			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
subjects affected / exposed	1 / 8569 (0.01%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma benign			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesothelioma malignant			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastases to adrenals			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lymph nodes			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lung			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to peritoneum			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to rectum			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to spinal cord			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to spine			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic bronchial carcinoma			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic carcinoma of the bladder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic gastric cancer			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 1	
Metastatic neoplasm			

subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic malignant melanoma			
subjects affected / exposed	5 / 8569 (0.06%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 2	0 / 2	
Metastatic renal cell carcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastatic squamous cell carcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monoclonal gammopathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelodysplastic syndrome			
subjects affected / exposed	0 / 8569 (0.00%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Myeloproliferative neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Nasopharyngeal cancer			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm malignant			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm prostate			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine tumour			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm skin			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine tumour of the lung			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Non-small cell lung cancer			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine tumour of the lung metastatic			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer metastatic			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ocular neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer recurrent			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oesophageal adenocarcinoma			
subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 1	
Oesophageal carcinoma			
subjects affected / exposed	4 / 8569 (0.05%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oesophageal squamous cell carcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral neoplasm benign			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal cancer			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoma			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian adenoma			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ovarian neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian epithelial cancer			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer metastatic			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pancreatic carcinoma			
subjects affected / exposed	8 / 8569 (0.09%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 5	0 / 5	
Pancreatic carcinoma metastatic			
subjects affected / exposed	9 / 8569 (0.11%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	0 / 10	0 / 9	
deaths causally related to treatment / all	0 / 6	0 / 7	
Pancreatic neoplasm			

subjects affected / exposed	0 / 8569 (0.00%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 2	
Pancreatic neuroendocrine tumour			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatoblastoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary cystadenoma lymphomatosum			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary renal cell carcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary serous endometrial carcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary tumour of renal pelvis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Parathyroid tumour benign			

subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile squamous cell carcinoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal carcinoma metastatic			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phaeochromocytoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal cancer			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pituitary tumour			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pituitary tumour benign			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell leukaemia			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Plasma cell myeloma			
subjects affected / exposed	6 / 8569 (0.07%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pleomorphic adenoma			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	55 / 8569 (0.64%)	69 / 8574 (0.80%)	
occurrences causally related to treatment / all	0 / 55	3 / 70	
deaths causally related to treatment / all	0 / 2	0 / 0	
Prostate cancer metastatic			
subjects affected / exposed	7 / 8569 (0.08%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 0	
Prostate cancer recurrent			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic adenoma			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	4 / 8569 (0.05%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenoma			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer			
subjects affected / exposed	4 / 8569 (0.05%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Rectal cancer metastatic			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal cancer			
subjects affected / exposed	7 / 8569 (0.08%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	0 / 8	1 / 10	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal cell carcinoma			
subjects affected / exposed	8 / 8569 (0.09%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	0 / 8	1 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal neoplasm			
subjects affected / exposed	4 / 8569 (0.05%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 4	1 / 6	
deaths causally related to treatment / all	0 / 1	0 / 0	
Retro-orbital neoplasm			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland cancer			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Salivary gland neoplasm			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sebacaceous carcinoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seborrhoeic keratosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Signet-ring cell carcinoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer			
subjects affected / exposed	3 / 8569 (0.04%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 2	0 / 2	
Small cell lung cancer extensive stage			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Small cell lung cancer metastatic			
subjects affected / exposed	4 / 8569 (0.05%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 3	0 / 0	
Soft tissue sarcoma			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestine adenocarcinoma			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Spinal cord neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	10 / 8569 (0.12%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	0 / 10	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of lung			
subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 2	
Squamous cell carcinoma of skin			
subjects affected / exposed	9 / 8569 (0.11%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 12	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
T-cell lymphoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the tongue			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Throat cancer			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid adenoma			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid cancer			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid cancer metastatic			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid neoplasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue neoplasm malignant stage unspecified			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			
subjects affected / exposed	12 / 8569 (0.14%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	5 / 14	3 / 11	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tonsil cancer			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell cancer of the renal pelvis and ureter			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma recurrent			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour obstruction			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma metastatic			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Uterine cancer			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal cancer stage 0			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cancer			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vocal cord neoplasm			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cancer stage 0			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer stage II			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma stage I			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Endometrial cancer stage I			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer stage III			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma stage III			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung carcinoma cell type unspecified stage IV			

subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Malignant neoplasm of ampulla of Vater			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-Hodgkin's lymphoma			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-Hodgkin's lymphoma stage IV			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer stage IV			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Prostate cancer stage IV			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm			
subjects affected / exposed	10 / 8569 (0.12%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 11	0 / 12	
deaths causally related to treatment / all	0 / 2	0 / 0	
Aortic aneurysm rupture			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiopathy			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic stenosis			
subjects affected / exposed	17 / 8569 (0.20%)	22 / 8574 (0.26%)	
occurrences causally related to treatment / all	0 / 17	0 / 22	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dilatation			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dissection			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial occlusive disease			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial insufficiency			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial thrombosis			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial perforation			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	5 / 8569 (0.06%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 1	
Arteritis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bleeding varicose vein			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure fluctuation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Claudication of jaw muscles			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	12 / 8569 (0.14%)	17 / 8574 (0.20%)	
occurrences causally related to treatment / all	0 / 12	2 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry gangrene			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic vascular disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Essential hypertension			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			
subjects affected / exposed	4 / 8569 (0.05%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral artery aneurysm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral artery embolism			

subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	6 / 8569 (0.07%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic vasculitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	27 / 8569 (0.32%)	27 / 8574 (0.31%)	
occurrences causally related to treatment / all	0 / 31	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypertensive crisis			
subjects affected / exposed	24 / 8569 (0.28%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	0 / 28	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency			
subjects affected / exposed	7 / 8569 (0.08%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	14 / 8569 (0.16%)	28 / 8574 (0.33%)	
occurrences causally related to treatment / all	1 / 14	2 / 29	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Iliac artery disease			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iliac artery embolism			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iliac artery occlusion			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			
subjects affected / exposed	3 / 8569 (0.04%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Internal haemorrhage			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemia			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ischaemic limb pain			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jugular vein thrombosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leriche syndrome			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphatic fistula			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoedema			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant hypertension			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microangiopathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	12 / 8569 (0.14%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 13	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	49 / 8569 (0.57%)	43 / 8574 (0.50%)	
occurrences causally related to treatment / all	0 / 53	0 / 56	
deaths causally related to treatment / all	0 / 1	0 / 0	
Peripheral artery aneurysm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery dissection			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery haematoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery occlusion			
subjects affected / exposed	15 / 8569 (0.18%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	0 / 20	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	20 / 8569 (0.23%)	23 / 8574 (0.27%)	
occurrences causally related to treatment / all	0 / 22	0 / 36	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	4 / 8569 (0.05%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			
subjects affected / exposed	19 / 8569 (0.22%)	34 / 8574 (0.40%)	
occurrences causally related to treatment / all	0 / 21	1 / 46	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	35 / 8569 (0.41%)	30 / 8574 (0.35%)	
occurrences causally related to treatment / all	0 / 41	0 / 32	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral venous disease			

subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phlebitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Raynaud's phenomenon			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 1	
Shock haemorrhagic			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Subclavian artery occlusion			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian steal syndrome			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian artery stenosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superior vena cava stenosis			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Temporal arteritis			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thromboangiitis obliterans			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose ulceration			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein			
subjects affected / exposed	5 / 8569 (0.06%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular occlusion			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasculitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasospasm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Hospitalisation			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			
subjects affected / exposed	10 / 8569 (0.12%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 10	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	

Chest pain			
subjects affected / exposed	20 / 8569 (0.23%)	29 / 8574 (0.34%)	
occurrences causally related to treatment / all	0 / 20	0 / 34	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac death			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Complication associated with device			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Critical illness			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	89 / 8569 (1.04%)	81 / 8574 (0.94%)	
occurrences causally related to treatment / all	0 / 89	0 / 81	
deaths causally related to treatment / all	0 / 89	0 / 81	
Dehiscence			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drowning			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Drug intolerance			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exercise tolerance decreased			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug withdrawal syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	5 / 8569 (0.06%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Generalised oedema			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernia			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Granuloma			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothermia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			

subjects affected / exposed	3 / 8569 (0.04%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site inflammation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated hernia			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammation			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device pain			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site irritation			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microlithiasis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			

subjects affected / exposed	8 / 8569 (0.09%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	1 / 8	0 / 9	
deaths causally related to treatment / all	0 / 5	0 / 4	
Necrobiosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrosis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	107 / 8569 (1.25%)	93 / 8574 (1.08%)	
occurrences causally related to treatment / all	1 / 120	0 / 110	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	5 / 8569 (0.06%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Organ failure			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pacemaker syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic mass			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral swelling			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	13 / 8569 (0.15%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 13	1 / 14	
deaths causally related to treatment / all	0 / 1	0 / 0	
Soft tissue inflammation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stent-graft endoleak			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Submandibular mass			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden cardiac death			
subjects affected / exposed	16 / 8569 (0.19%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	0 / 16	0 / 14	
deaths causally related to treatment / all	0 / 16	0 / 14	
Sudden death			

subjects affected / exposed	23 / 8569 (0.27%)	21 / 8574 (0.24%)	
occurrences causally related to treatment / all	0 / 23	0 / 21	
deaths causally related to treatment / all	0 / 23	0 / 21	
Systemic inflammatory response syndrome			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent occlusion			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent stenosis			
subjects affected / exposed	8 / 8569 (0.09%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	1 / 8	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent thrombosis			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Allergy to metals			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Allergy to vaccine			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic reaction			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic shock			

subjects affected / exposed	5 / 8569 (0.06%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Drug hypersensitivity			
subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hashitoxicosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoidosis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Acquired hydrocele			
subjects affected / exposed	5 / 8569 (0.06%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acquired phimosis			
subjects affected / exposed	1 / 8569 (0.01%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 1	2 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balanoposthitis			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	1 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign prostatic hyperplasia			

subjects affected / exposed	31 / 8569 (0.36%)	28 / 8574 (0.33%)	
occurrences causally related to treatment / all	0 / 31	0 / 30	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast mass			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast pain			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical dysplasia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colpocele			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystocele			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial hyperplasia			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial hypertrophy			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erectile dysfunction			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Female genital tract fistula			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gynaecomastia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrosalpinx			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic haemorrhage			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic prolapse			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile necrosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peyronie's disease			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postmenopausal haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			
subjects affected / exposed	8 / 8569 (0.09%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	2 / 9	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatomegaly			
subjects affected / exposed	5 / 8569 (0.06%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectocele			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Testicular cyst			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine polyp			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse			

subjects affected / exposed	2 / 8569 (0.02%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterovaginal prolapse			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal dysplasia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal prolapse			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicocele			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	8 / 8569 (0.09%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	1 / 8	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute respiratory distress syndrome			
subjects affected / exposed	4 / 8569 (0.05%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 2	0 / 0	
Acute respiratory failure			
subjects affected / exposed	43 / 8569 (0.50%)	37 / 8574 (0.43%)	
occurrences causally related to treatment / all	0 / 50	0 / 41	
deaths causally related to treatment / all	0 / 12	0 / 5	
Alveolitis allergic			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Apnoea			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspiration			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	18 / 8569 (0.21%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 21	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma-chronic obstructive pulmonary disease overlap syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthmatic crisis			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atelectasis			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial hyperreactivity			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis chronic			

subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiectasis			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	54 / 8569 (0.63%)	54 / 8574 (0.63%)	
occurrences causally related to treatment / all	0 / 90	1 / 81	
deaths causally related to treatment / all	0 / 5	0 / 5	
Chronic respiratory failure			
subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dyspnoea			
subjects affected / exposed	21 / 8569 (0.25%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 22	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 1	
Dyspnoea exertional			
subjects affected / exposed	5 / 8569 (0.06%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	5 / 8569 (0.06%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysema			

subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	2 / 8569 (0.02%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Haemothorax			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrothorax			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	5 / 8569 (0.06%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Hypoxia			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infiltration			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal polyps			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraneoplastic pleural effusion			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Obstructive airways disorder			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal septum deviation			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pickwickian syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	13 / 8569 (0.15%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 14	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pleural thickening			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			

subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleuritic pain			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	10 / 8569 (0.12%)	18 / 8574 (0.21%)	
occurrences causally related to treatment / all	0 / 10	0 / 19	
deaths causally related to treatment / all	0 / 2	0 / 2	
Pulmonary amyloidosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	5 / 8569 (0.06%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	4 / 8569 (0.05%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary arterial hypertension			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary congestion			
subjects affected / exposed	0 / 8569 (0.00%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			

subjects affected / exposed	27 / 8569 (0.32%)	26 / 8574 (0.30%)	
occurrences causally related to treatment / all	0 / 27	1 / 26	
deaths causally related to treatment / all	0 / 8	0 / 5	
Pulmonary hypertension			
subjects affected / exposed	4 / 8569 (0.05%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 19	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary haemorrhage			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary fibrosis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary infarction			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary mass			
subjects affected / exposed	11 / 8569 (0.13%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 11	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reflux laryngitis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	15 / 8569 (0.18%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	2 / 16	0 / 4	
deaths causally related to treatment / all	1 / 4	0 / 0	
Pulmonary thrombosis			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory acidosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory arrest			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory distress			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	24 / 8569 (0.28%)	29 / 8574 (0.34%)	
occurrences causally related to treatment / all	0 / 28	1 / 30	
deaths causally related to treatment / all	0 / 9	0 / 7	
Restrictive pulmonary disease			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid lung			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinitis hypertrophic			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep apnoea syndrome			

subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord leukoplakia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Acute psychosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adjustment disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Agitation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol withdrawal syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Completed suicide			

subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Confusional state			
subjects affected / exposed	12 / 8569 (0.14%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	2 / 12	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conversion disorder			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	4 / 8569 (0.05%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depressed mood			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	13 / 8569 (0.15%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 15	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug abuse			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomania			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			
subjects affected / exposed	6 / 8569 (0.07%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	7 / 8569 (0.08%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Mood disorder due to a general medical condition			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Panic attack			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-traumatic stress disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Restlessness			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Schizoaffective disorder			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Schizophrenia			

subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Schizoaffective disorder depressive type			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep disorder			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device breakage			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device dislocation			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device failure			

subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device lead damage			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device occlusion			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stent malfunction			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stenosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stone			
subjects affected / exposed	8 / 8569 (0.09%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	0 / 8	1 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			

subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary dyskinesia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary dyspepsia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	5 / 8569 (0.06%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 6	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 2	1 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cholecystitis			
subjects affected / exposed	22 / 8569 (0.26%)	18 / 8574 (0.21%)	
occurrences causally related to treatment / all	0 / 23	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	22 / 8569 (0.26%)	25 / 8574 (0.29%)	
occurrences causally related to treatment / all	0 / 22	0 / 25	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	6 / 8569 (0.07%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			

subjects affected / exposed	38 / 8569 (0.44%)	26 / 8574 (0.30%)	
occurrences causally related to treatment / all	1 / 40	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatic failure			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder cholesterolosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder perforation			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder polyp			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			
subjects affected / exposed	11 / 8569 (0.13%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	2 / 13	0 / 8	
deaths causally related to treatment / all	0 / 3	0 / 1	
Hepatic cyst			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			

subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatic fibrosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic mass			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic steatosis			
subjects affected / exposed	4 / 8569 (0.05%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatorenal syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocholecystis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic hepatitis			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver injury			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-alcoholic steatohepatitis			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Porcelain gallbladder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portal vein thrombosis			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Anticoagulation drug level below therapeutic			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose abnormal			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose increased			
subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure increased			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure decreased			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheterisation cardiac			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain natriuretic peptide increased			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical condition abnormal			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Glomerular filtration rate decreased			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio increased			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transaminases increased			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			
subjects affected / exposed	7 / 8569 (0.08%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 8	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urine cytology abnormal			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram QT prolonged			

subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram ST segment elevation			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis C antibody positive			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin I increased			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin T increased			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Abdominal injury			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall wound			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wound dehiscence			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental overdose			

subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental poisoning			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acetabulum fracture			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Allergic transfusion reaction			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia postoperative			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anastomotic leak			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anastomotic ulcer			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			

subjects affected / exposed	14 / 8569 (0.16%)	19 / 8574 (0.22%)	
occurrences causally related to treatment / all	0 / 14	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial bypass occlusion			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial injury			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial restenosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back injury			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Avulsion fracture			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone contusion			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns second degree			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain contusion			

subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac procedure complication			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac valve replacement complication			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery restenosis			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cartilage injury			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract operation complication			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			
subjects affected / exposed	4 / 8569 (0.05%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cement embolism			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest crushing			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Chest injury			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complications of transplanted liver			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Compression fracture			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	7 / 8569 (0.08%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	4 / 8569 (0.05%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusion postoperative			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery restenosis			

subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary bypass stenosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costal cartilage fracture			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	3 / 8569 (0.04%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 3	
Cystitis radiation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exposure to toxic agent			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extradural haematoma			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eyelid injury			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			

subjects affected / exposed	4 / 8569 (0.05%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	0 / 4	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	9 / 8569 (0.11%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	20 / 8569 (0.23%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	1 / 20	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	18 / 8569 (0.21%)	16 / 8574 (0.19%)	
occurrences causally related to treatment / all	1 / 18	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula fracture			
subjects affected / exposed	4 / 8569 (0.05%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	5 / 8569 (0.06%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body in gastrointestinal tract			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body in respiratory tract			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture displacement			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fractured sacrum			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gun shot wound			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haematuria traumatic			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			
subjects affected / exposed	4 / 8569 (0.05%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 4	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heat stroke			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	8 / 8569 (0.09%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 2	0 / 0	
Hip fracture			
subjects affected / exposed	15 / 8569 (0.18%)	13 / 8574 (0.15%)	
occurrences causally related to treatment / all	0 / 16	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ilium fracture			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	20 / 8569 (0.23%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	2 / 20	1 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Incisional hernia			
subjects affected / exposed	2 / 8569 (0.02%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional overdose			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaw fracture			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	1 / 8569 (0.01%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laceration			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament sprain			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb crushing injury			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb fracture			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	4 / 8569 (0.05%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 4	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb traumatic amputation			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lisfranc fracture			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			

subjects affected / exposed	9 / 8569 (0.11%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	6 / 8569 (0.07%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	2 / 8569 (0.02%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle strain			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle rupture			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve injury			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular procedural complication			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	6 / 8569 (0.07%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	1 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	4 / 8569 (0.05%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital haematoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periprocedural myocardial infarction			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery restenosis			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periprosthetic fracture			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax traumatic			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumoconiosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post concussion syndrome			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural complication			
subjects affected / exposed	14 / 8569 (0.16%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	0 / 14	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
Post laminectomy syndrome			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural constipation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural discharge			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	1 / 8569 (0.01%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematuria			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	4 / 8569 (0.05%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 5	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 1	
Post procedural inflammation			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural myocardial infarction			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative ileus			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative delirium			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative respiratory failure			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative thoracic procedure complication			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative thrombosis			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound complication			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural complication			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pain			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pneumothorax			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural shock			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pubis fracture			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation oesophagitis			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal laceration postoperative			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	10 / 8569 (0.12%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 10	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	15 / 8569 (0.18%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 17	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	7 / 8569 (0.08%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 3	0 / 2	
Sedation complication			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin abrasion			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin injury			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin wound			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	6 / 8569 (0.07%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fractured base			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue injury			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column injury			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	4 / 8569 (0.05%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 4	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	4 / 8569 (0.05%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic injury			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic rupture			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stab wound			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sternal fracture			
subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stoma site haemorrhage			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	9 / 8569 (0.11%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 9	1 / 6	
deaths causally related to treatment / all	0 / 1	0 / 1	
Subcutaneous haematoma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	11 / 8569 (0.13%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	0 / 13	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 1	
Subdural haemorrhage			

subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Tendon injury			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	8 / 8569 (0.09%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			
subjects affected / exposed	6 / 8569 (0.07%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	5 / 8569 (0.06%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 5	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue injury			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transfusion reaction			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transplant dysfunction			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic arthritis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic fracture			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haemothorax			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic intracranial haemorrhage			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	4 / 8569 (0.05%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft occlusion			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft restenosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft thrombosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	5 / 8569 (0.06%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound dehiscence			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound haematoma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound necrosis			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			

subjects affected / exposed	5 / 8569 (0.06%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Adenomatous polyposis coli			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital hepatobiliary anomaly			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart disease congenital			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocele			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertrophic cardiomyopathy			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitello-intestinal duct remnant			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis Meckel's			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			

Acute cardiac event			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute coronary syndrome			
subjects affected / exposed	31 / 8569 (0.36%)	17 / 8574 (0.20%)	
occurrences causally related to treatment / all	0 / 33	0 / 22	
deaths causally related to treatment / all	0 / 4	0 / 1	
Acute left ventricular failure			
subjects affected / exposed	17 / 8569 (0.20%)	16 / 8574 (0.19%)	
occurrences causally related to treatment / all	0 / 23	0 / 22	
deaths causally related to treatment / all	0 / 1	0 / 1	
Acute myocardial infarction			
subjects affected / exposed	233 / 8569 (2.72%)	265 / 8574 (3.09%)	
occurrences causally related to treatment / all	7 / 264	3 / 293	
deaths causally related to treatment / all	0 / 18	0 / 24	
Angina pectoris			
subjects affected / exposed	159 / 8569 (1.86%)	154 / 8574 (1.80%)	
occurrences causally related to treatment / all	1 / 175	0 / 178	
deaths causally related to treatment / all	0 / 1	0 / 0	
Angina unstable			
subjects affected / exposed	269 / 8569 (3.14%)	271 / 8574 (3.16%)	
occurrences causally related to treatment / all	4 / 332	2 / 349	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve calcification			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve disease			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve disease mixed			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve incompetence			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	2 / 8569 (0.02%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	6 / 8569 (0.07%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 3	0 / 1	
Arteriosclerosis coronary artery			
subjects affected / exposed	16 / 8569 (0.19%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	1 / 21	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Atrial fibrillation			
subjects affected / exposed	139 / 8569 (1.62%)	117 / 8574 (1.36%)	
occurrences causally related to treatment / all	3 / 177	1 / 138	
deaths causally related to treatment / all	0 / 1	0 / 2	
Atrial flutter			
subjects affected / exposed	34 / 8569 (0.40%)	21 / 8574 (0.24%)	
occurrences causally related to treatment / all	0 / 44	1 / 25	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial tachycardia			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial thrombosis			

subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	7 / 8569 (0.08%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 7	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	14 / 8569 (0.16%)	19 / 8574 (0.22%)	
occurrences causally related to treatment / all	0 / 14	0 / 19	
deaths causally related to treatment / all	0 / 1	0 / 0	
Atrioventricular block second degree			
subjects affected / exposed	7 / 8569 (0.08%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	0 / 7	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradyarrhythmia			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	21 / 8569 (0.25%)	16 / 8574 (0.19%)	
occurrences causally related to treatment / all	0 / 22	1 / 17	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bifascicular block			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block right			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	31 / 8569 (0.36%)	33 / 8574 (0.38%)	
occurrences causally related to treatment / all	1 / 32	1 / 34	
deaths causally related to treatment / all	0 / 19	1 / 28	
Cardiac asthma			
subjects affected / exposed	5 / 8569 (0.06%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 8	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorder			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	188 / 8569 (2.19%)	147 / 8574 (1.71%)	
occurrences causally related to treatment / all	4 / 252	2 / 199	
deaths causally related to treatment / all	0 / 12	0 / 24	
Cardiac failure acute			
subjects affected / exposed	31 / 8569 (0.36%)	22 / 8574 (0.26%)	
occurrences causally related to treatment / all	0 / 39	0 / 25	
deaths causally related to treatment / all	0 / 7	0 / 6	
Cardiac failure congestive			
subjects affected / exposed	147 / 8569 (1.72%)	121 / 8574 (1.41%)	
occurrences causally related to treatment / all	4 / 205	0 / 177	
deaths causally related to treatment / all	0 / 9	0 / 12	
Cardiac failure chronic			
subjects affected / exposed	20 / 8569 (0.23%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 23	1 / 14	
deaths causally related to treatment / all	0 / 2	0 / 0	
Cardiac ventricular thrombosis			

subjects affected / exposed	5 / 8569 (0.06%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac tamponade			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	11 / 8569 (0.13%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	1 / 11	0 / 12	
deaths causally related to treatment / all	0 / 8	0 / 12	
Cardiogenic shock			
subjects affected / exposed	13 / 8569 (0.15%)	19 / 8574 (0.22%)	
occurrences causally related to treatment / all	0 / 16	0 / 19	
deaths causally related to treatment / all	0 / 6	0 / 14	
Cardiomegaly			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiomyopathy			
subjects affected / exposed	8 / 8569 (0.09%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiomyopathy acute			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	7 / 8569 (0.08%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 6	0 / 2	
Cardiovascular insufficiency			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiovascular disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronotropic incompetence			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic left ventricular failure			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Congestive cardiomyopathy			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Conduction disorder			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cor pulmonale			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery aneurysm			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery occlusion			

subjects affected / exposed	5 / 8569 (0.06%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	84 / 8569 (0.98%)	106 / 8574 (1.24%)	
occurrences causally related to treatment / all	1 / 87	5 / 113	
deaths causally related to treatment / all	1 / 3	0 / 5	
Coronary artery stenosis			
subjects affected / exposed	22 / 8569 (0.26%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 23	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery thrombosis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Coronary ostial stenosis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dressler's syndrome			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diastolic dysfunction			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extrasystoles			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart valve incompetence			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart valve stenosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive heart disease			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cardiomyopathy			
subjects affected / exposed	18 / 8569 (0.21%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	0 / 18	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 1	
Left ventricular failure			
subjects affected / exposed	13 / 8569 (0.15%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 13	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	6 / 8569 (0.07%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve stenosis			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			

subjects affected / exposed	108 / 8569 (1.26%)	96 / 8574 (1.12%)
occurrences causally related to treatment / all	2 / 111	1 / 104
deaths causally related to treatment / all	0 / 24	0 / 19
Myocarditis		
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Myocardial ischaemia		
subjects affected / exposed	54 / 8569 (0.63%)	47 / 8574 (0.55%)
occurrences causally related to treatment / all	0 / 61	0 / 49
deaths causally related to treatment / all	0 / 3	0 / 4
Nodal arrhythmia		
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Palpitations		
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)
occurrences causally related to treatment / all	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Pericardial effusion		
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)
occurrences causally related to treatment / all	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pericarditis		
subjects affected / exposed	4 / 8569 (0.05%)	8 / 8574 (0.09%)
occurrences causally related to treatment / all	0 / 5	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0
Postinfarction angina		
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Prinzmetal angina		

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulseless electrical activity			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatic heart disease			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Right ventricular failure			
subjects affected / exposed	4 / 8569 (0.05%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	1 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sinus arrest			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus bradycardia			
subjects affected / exposed	5 / 8569 (0.06%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			
subjects affected / exposed	13 / 8569 (0.15%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	0 / 14	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			

subjects affected / exposed	6 / 8569 (0.07%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 7	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	5 / 8569 (0.06%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Torsade de pointes			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tricuspid valve incompetence			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trifascicular block			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ventricular extrasystoles			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular failure			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	9 / 8569 (0.11%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	0 / 11	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 4	
Ventricular tachycardia			
subjects affected / exposed	15 / 8569 (0.18%)	19 / 8574 (0.22%)	
occurrences causally related to treatment / all	1 / 21	0 / 23	
deaths causally related to treatment / all	0 / 0	0 / 1	
Adams-Stokes syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amyotrophic lateral sclerosis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aphasia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arachnoid cyst			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ataxia			

subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autonomic failure syndrome			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal ganglia infarction			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basilar artery perforation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Brain injury			
subjects affected / exposed	6 / 8569 (0.07%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 2	0 / 0	
Brain oedema			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Brain stem infarction			
subjects affected / exposed	3 / 8569 (0.04%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain stem haemorrhage			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain stem stroke			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid arteriosclerosis			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burning sensation			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery occlusion			
subjects affected / exposed	1 / 8569 (0.01%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	21 / 8569 (0.25%)	27 / 8574 (0.31%)	
occurrences causally related to treatment / all	0 / 22	0 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery insufficiency			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid sinus syndrome			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			

subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar ataxia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar infarction			
subjects affected / exposed	2 / 8569 (0.02%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cerebellar stroke			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral artery embolism			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral artery occlusion			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral atrophy			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haematoma			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	6 / 8569 (0.07%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 2	
Cerebral infarction			
subjects affected / exposed	32 / 8569 (0.37%)	24 / 8574 (0.28%)	
occurrences causally related to treatment / all	2 / 33	1 / 27	
deaths causally related to treatment / all	0 / 3	0 / 4	
Cerebral ischaemia			
subjects affected / exposed	9 / 8569 (0.11%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 10	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	88 / 8569 (1.03%)	102 / 8574 (1.19%)	
occurrences causally related to treatment / all	3 / 94	2 / 112	
deaths causally related to treatment / all	0 / 11	0 / 10	
Cerebrovascular disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular insufficiency			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical cord compression			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical radiculopathy			

subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicobrachial syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cluster headache			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cranial nerve palsies multiple			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Demyelinating polyneuropathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic autonomic neuropathy			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic hyperosmolar coma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic coma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	4 / 8569 (0.05%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	9 / 8569 (0.11%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	1 / 9	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness postural			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dystonic tremor			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolic stroke			

subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	8 / 8569 (0.09%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	5 / 8569 (0.06%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Essential tremor			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	8 / 8569 (0.09%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paresis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Focal dyscognitive seizures			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised tonic-clonic seizure			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			

subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic cerebral infarction			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic stroke			
subjects affected / exposed	11 / 8569 (0.13%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 11	0 / 5	
deaths causally related to treatment / all	0 / 2	0 / 3	
Haemorrhagic transformation stroke			
subjects affected / exposed	4 / 8569 (0.05%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Headache			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemianopia homonymous			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			

subjects affected / exposed	4 / 8569 (0.05%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypoaesthesia			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive encephalopathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic coma			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic unconsciousness			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic encephalopathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokinesia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Intensive care unit acquired weakness			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial aneurysm			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intraventricular haemorrhage			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
Ischaemic cerebral infarction			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic neuropathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	90 / 8569 (1.05%)	97 / 8574 (1.13%)	
occurrences causally related to treatment / all	0 / 99	2 / 105	
deaths causally related to treatment / all	0 / 7	0 / 6	
Lacunar infarction			
subjects affected / exposed	14 / 8569 (0.16%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	0 / 14	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lateral medullary syndrome			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar stroke			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	6 / 8569 (0.07%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	6 / 8569 (0.07%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lumbosacral radiculopathy			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medication overuse headache			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Memory impairment			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy			
subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple system atrophy			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myasthenia gravis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle contractions involuntary			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve compression			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorder			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurological symptom			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurodegenerative disorder			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normal pressure hydrocephalus			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Occipital neuralgia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraparesis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinson's disease			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Partial seizures			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peroneal nerve palsy			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post herpetic neuralgia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postictal paralysis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Quadriplegia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular pain			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular syndrome			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			

subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ruptured cerebral aneurysm			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sciatica			
subjects affected / exposed	7 / 8569 (0.08%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	10 / 8569 (0.12%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	1 / 10	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Simple partial seizures			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somnolence			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal claudication			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitic myelopathy			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stiff person syndrome			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Status epilepticus			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural hygroma			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stroke in evolution			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	41 / 8569 (0.48%)	37 / 8574 (0.43%)	
occurrences causally related to treatment / all	2 / 44	3 / 38	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thalamic infarction			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic outlet syndrome			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tension headache			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic encephalopathy			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombotic stroke			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Thrombotic cerebral infarction			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic neuropathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	54 / 8569 (0.63%)	68 / 8574 (0.79%)	
occurrences causally related to treatment / all	1 / 59	1 / 76	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vascular encephalopathy			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular dementia			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral artery stenosis			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord paralysis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			
subjects affected / exposed	5 / 8569 (0.06%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia Alzheimer's type			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia with Lewy bodies			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Guillain-Barre syndrome			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
IIIrd nerve paralysis			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIth nerve paralysis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIth nerve paresis			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo CNS origin			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wernicke-Korsakoff syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			
subjects affected / exposed	28 / 8569 (0.33%)	20 / 8574 (0.23%)	
occurrences causally related to treatment / all	0 / 30	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia of chronic disease			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulopathy			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Elephantiasis			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hilar lymphadenopathy			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic anaemia			
subjects affected / exposed	4 / 8569 (0.05%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	4 / 8569 (0.05%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune thrombocytopenic purpura			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	18 / 8569 (0.21%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 18	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy mediastinal			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			

subjects affected / exposed	1 / 8569 (0.01%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normocytic anaemia			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microcytic anaemia			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasmacytosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic cyst			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic infarction			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenic purpura			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia vitamin B12 deficiency			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deafness neurosensory			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoacusis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden hearing loss			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tinnitus			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			

subjects affected / exposed	12 / 8569 (0.14%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 13	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo labyrinthine			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	8 / 8569 (0.09%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	1 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular ataxia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular disorder			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Amaurosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amblyopia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amaurosis fugax			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blindness transient			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Astigmatism			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	26 / 8569 (0.30%)	28 / 8574 (0.33%)	
occurrences causally related to treatment / all	0 / 32	0 / 31	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract nuclear			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract subcapsular			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Corneal deposits			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dacryostenosis acquired			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinal oedema			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinopathy			

subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diplopia			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine ophthalmopathy			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exophthalmos			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye haemorrhage			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iridocyclitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iritis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lagophthalmos			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular fibrosis			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular degeneration			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular oedema			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Maculopathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			
subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal haemorrhage			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal tear			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vascular occlusion			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tractional retinal detachment			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein occlusion			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulcerative keratitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vision blurred			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual impairment			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	6 / 8569 (0.07%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tolosa-Hunt syndrome			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal adhesions			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal incarcerated hernia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	7 / 8569 (0.08%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia obstructive			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain lower			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	9 / 8569 (0.11%)	13 / 8574 (0.15%)	
occurrences causally related to treatment / all	0 / 9	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			

subjects affected / exposed	5 / 8569 (0.06%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute haemorrhagic ulcerative colitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcoholic pancreatitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fissure			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Barrett's oesophagus			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	11 / 8569 (0.13%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 11	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis microscopic			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	2 / 8569 (0.02%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	3 / 8569 (0.04%)	13 / 8574 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ulcerative			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gastroenteropathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gastroparesis			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dieulafoy's vascular malformation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	11 / 8569 (0.13%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	1 / 11	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal haemorrhagic			

subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	2 / 8569 (0.02%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer perforation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	2 / 8569 (0.02%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			

subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocutaneous fistula			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterovesical fistula			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epigastric discomfort			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiplonic appendagitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecaloma			
subjects affected / exposed	0 / 8569 (0.00%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faeces discoloured			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			

subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastric perforation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric polyps			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric stenosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	11 / 8569 (0.13%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	0 / 11	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	20 / 8569 (0.23%)	13 / 8574 (0.15%)	
occurrences causally related to treatment / all	1 / 20	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			

subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal angiodysplasia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	18 / 8569 (0.21%)	17 / 8574 (0.20%)	
occurrences causally related to treatment / all	0 / 18	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal inflammation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal necrosis			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal obstruction			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal perforation			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal ulcer haemorrhage			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	10 / 8569 (0.12%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 10	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingival bleeding			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernial eventration			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia			

subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus paralytic			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	13 / 8569 (0.15%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	0 / 13	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal fibrosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal infarction			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Intestinal ischaemia			
subjects affected / exposed	1 / 8569 (0.01%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	4 / 8569 (0.05%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal polyp			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal pseudo-obstruction			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal fluid collection			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jejunal perforation			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal haemorrhage			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intussusception			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal ulcer			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal ulcer haemorrhage			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	9 / 8569 (0.11%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 9	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lumbar hernia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric artery embolism			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Mesenteric artery stenosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric panniculitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric vascular insufficiency			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Obstruction gastric			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive pancreatitis			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Odynophagia			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal food impaction			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal obstruction			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal perforation			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal varices haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic cyst			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis ulcerative			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palatal oedema			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic duct obstruction			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic pseudocyst			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic necrosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	12 / 8569 (0.14%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	1 / 12	1 / 12	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatitis acute			
subjects affected / exposed	15 / 8569 (0.18%)	13 / 8574 (0.15%)	
occurrences causally related to treatment / all	1 / 17	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pancreatitis relapsing			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis chronic			

subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis necrotising			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatolithiasis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontal disease			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal adhesions			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumoperitoneum			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portal hypertensive gastropathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	2 / 8569 (0.02%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haematoma			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Retroperitoneal haemorrhage			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland cyst			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	9 / 8569 (0.11%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	0 / 9	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal haemorrhage			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestine ulcer			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal perforation			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Steatorrhoea			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis mesenteric vessel			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Umbilical hernia			
subjects affected / exposed	9 / 8569 (0.11%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 10	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	9 / 8569 (0.11%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 9	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varices oesophageal			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	8 / 8569 (0.09%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Mallory-Weiss syndrome			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angioedema			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decubitus ulcer			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermal cyst			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis contact			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic bullosis			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	29 / 8569 (0.34%)	37 / 8574 (0.43%)	
occurrences causally related to treatment / all	0 / 34	0 / 45	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ulcer			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema multiforme			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fixed eruption			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hidradenitis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity vasculitis			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic skin ulcer			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keloid scar			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lichen planus			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lichen sclerosus			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melanocytic hyperplasia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic ulcer			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Purpura			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyoderma gangrenosum			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin swelling			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	23 / 8569 (0.27%)	24 / 8574 (0.28%)	
occurrences causally related to treatment / all	0 / 26	1 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stasis dermatitis			

subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic skin eruption			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Henoch-Schonlein purpura			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	127 / 8569 (1.48%)	94 / 8574 (1.10%)	
occurrences causally related to treatment / all	21 / 152	10 / 96	
deaths causally related to treatment / all	1 / 6	1 / 4	
Azotaemia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder outlet obstruction			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder perforation			

subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder mass			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder prolapse			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urethral			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus bladder			
subjects affected / exposed	6 / 8569 (0.07%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Calculus urinary			
subjects affected / exposed	4 / 8569 (0.05%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	1 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	13 / 8569 (0.15%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	1 / 17	1 / 10	
deaths causally related to treatment / all	0 / 2	0 / 0	
Cystitis glandularis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis noninfective			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis haemorrhagic			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis ulcerative			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
End stage renal disease			
subjects affected / exposed	7 / 8569 (0.08%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	1 / 8	0 / 3	
deaths causally related to treatment / all	1 / 3	0 / 0	
Dysuria			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic nephropathy			
subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Glomerulonephritis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	16 / 8569 (0.19%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 19	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			

subjects affected / exposed	6 / 8569 (0.07%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 6	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower urinary tract symptoms			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myeloma cast nephropathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketonuria			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	18 / 8569 (0.21%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	0 / 18	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedematous kidney			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvi-ureteric obstruction			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proteinuria			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pollakiuria			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	5 / 8569 (0.06%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst ruptured			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal disorder			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	17 / 8569 (0.20%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	1 / 17	2 / 11	
deaths causally related to treatment / all	0 / 2	0 / 1	
Renal haematoma			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	12 / 8569 (0.14%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	2 / 12	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal infarct			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal injury			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal tubular acidosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal tubular necrosis			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress urinary incontinence			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric stenosis			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			

subjects affected / exposed	17 / 8569 (0.20%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	1 / 21	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral meatus stenosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral obstruction			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	5 / 8569 (0.06%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary bladder haemorrhage			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary bladder polyp			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	10 / 8569 (0.12%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	1 / 10	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal mass			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenomegaly			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basedow's disease			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Goitre			
subjects affected / exposed	8 / 8569 (0.09%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperadrenalism			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypopituitarism			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism primary			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid mass			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic nodular goitre			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	9 / 8569 (0.11%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	0 / 9	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthralgia			
subjects affected / exposed	2 / 8569 (0.02%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Articular calcification			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropathy			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis reactive			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	6 / 8569 (0.07%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	3 / 8569 (0.04%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	9 / 8569 (0.11%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 9	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondromalacia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondropathy			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Compartment syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diastasis recti abdominis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			

subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dupuytren's contracture			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extraskkeletal ossification			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facet joint syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fasciitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture malunion			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture nonunion			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	4 / 8569 (0.05%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemarthrosis			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc compression			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	6 / 8569 (0.07%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorder			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc displacement			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	17 / 8569 (0.20%)	24 / 8574 (0.28%)	
occurrences causally related to treatment / all	0 / 18	0 / 25	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaw cyst			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament calcification			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint ankylosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint contracture			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscal degeneration			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	18 / 8569 (0.21%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	0 / 18	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle fibrosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mobility decreased			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasms			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle haemorrhage			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	6 / 8569 (0.07%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	24 / 8569 (0.28%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 25	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic arthropathy			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myositis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondrosis			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteitis			
subjects affected / exposed	4 / 8569 (0.05%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	92 / 8569 (1.07%)	103 / 8574 (1.20%)	
occurrences causally related to treatment / all	0 / 102	1 / 114	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteolysis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporotic fracture			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in jaw			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periarthritis			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patellofemoral pain syndrome			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthritis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyalgia rheumatica			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudarthrosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			

subjects affected / exposed	4 / 8569 (0.05%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 1	
Rhabdomyolysis			
subjects affected / exposed	7 / 8569 (0.08%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriatic arthropathy			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sjogren's syndrome			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	12 / 8569 (0.14%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 13	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	16 / 8569 (0.19%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 16	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal ligament ossification			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	3 / 8569 (0.04%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			

subjects affected / exposed	5 / 8569 (0.06%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendonitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tenosynovitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trigger finger			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tenosynovitis stenosans			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral foraminal stenosis			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral lesion			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immunoglobulin G4 related disease			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal sepsis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Abdominal wall abscess			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	9 / 8569 (0.11%)	8 / 8574 (0.09%)	
occurrences causally related to treatment / all	1 / 10	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acquired immunodeficiency syndrome			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute endocarditis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute sinusitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amoebiasis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	5 / 8569 (0.06%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendiceal abscess			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	12 / 8569 (0.14%)	12 / 8574 (0.14%)	
occurrences causally related to treatment / all	0 / 12	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			

subjects affected / exposed	11 / 8569 (0.13%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 13	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis infective			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspergilloma			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	3 / 8569 (0.04%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterascites			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial colitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial tracheitis			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteriuria			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Beta haemolytic streptococcal infection			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary sepsis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bone abscess			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain abscess			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast abscess			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	35 / 8569 (0.41%)	15 / 8574 (0.17%)	
occurrences causally related to treatment / all	0 / 35	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis bacterial			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis viral			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burn infection			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis infective			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter gastroenteritis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	93 / 8569 (1.09%)	84 / 8574 (0.98%)	
occurrences causally related to treatment / all	2 / 117	0 / 100	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis gangrenous			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis of male external genital organ			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis orbital			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis staphylococcal			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central nervous system infection			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest wall abscess			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis infective			
subjects affected / exposed	3 / 8569 (0.04%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 0	
Chronic sinusitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridial sepsis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Clostridium difficile colitis			
subjects affected / exposed	2 / 8569 (0.02%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			

subjects affected / exposed	1 / 8569 (0.01%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cystitis			
subjects affected / exposed	3 / 8569 (0.04%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	0 / 3	1 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus viraemia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue fever			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	13 / 8569 (0.15%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	0 / 13	1 / 11	
deaths causally related to treatment / all	0 / 1	0 / 0	
Device related infection			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gangrene			
subjects affected / exposed	11 / 8569 (0.13%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 11	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			

subjects affected / exposed	20 / 8569 (0.23%)	20 / 8574 (0.23%)	
occurrences causally related to treatment / all	0 / 22	1 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis intestinal haemorrhagic			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Empyema			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalitis			
subjects affected / exposed	4 / 8569 (0.05%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 3	0 / 0	
Encephalomyelitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Endocarditis bacterial			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Endocarditis enterococcal			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis staphylococcal			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometritis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis infectious			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal bacteraemia			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal sepsis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiglottitis			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia bacteraemia			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			

subjects affected / exposed	13 / 8569 (0.15%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 13	1 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			
subjects affected / exposed	0 / 8569 (0.00%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	1 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
External ear cellulitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extradural abscess			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fungal infection			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	30 / 8569 (0.35%)	22 / 8574 (0.26%)	
occurrences causally related to treatment / all	0 / 40	0 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gas gangrene			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric infection			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	27 / 8569 (0.32%)	26 / 8574 (0.30%)	
occurrences causally related to treatment / all	0 / 27	2 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis salmonella			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	5 / 8569 (0.06%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Giardiasis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Helicobacter infection			

subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma infection			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis viral			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Human anaplasmosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site infection			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	6 / 8569 (0.07%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious colitis			

subjects affected / exposed	2 / 8569 (0.02%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective gastroduodenitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	15 / 8569 (0.18%)	17 / 8574 (0.20%)	
occurrences causally related to treatment / all	0 / 15	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral discitis			
subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Klebsiella bacteraemia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella sepsis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Legionella infection			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			

subjects affected / exposed	4 / 8569 (0.05%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
Localised infection			
subjects affected / exposed	10 / 8569 (0.12%)	16 / 8574 (0.19%)	
occurrences causally related to treatment / all	0 / 11	0 / 16	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	10 / 8569 (0.12%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	0 / 10	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung abscess			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lyme disease			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaria			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastoiditis			

subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site abscess			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site infection			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site joint infection			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis aseptic			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis pneumococcal			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Meningitis viral			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucormycosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle abscess			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising fasciitis			
subjects affected / exposed	5 / 8569 (0.06%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	1 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurosyphilis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic sepsis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
subjects affected / exposed	0 / 8569 (0.00%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Onychomycosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral candidiasis			

subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal candidiasis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	39 / 8569 (0.46%)	26 / 8574 (0.30%)	
occurrences causally related to treatment / all	1 / 46	0 / 35	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis acute			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis chronic			
subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media chronic			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic abscess			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parotitis			
subjects affected / exposed	3 / 8569 (0.04%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic abscess			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic inflammatory disease			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perineal abscess			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Perinephric abscess			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontitis			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	5 / 8569 (0.06%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Peritonitis bacterial			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillar abscess			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy viral			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumococcal infection			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumococcal sepsis			
subjects affected / exposed	0 / 8569 (0.00%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			

subjects affected / exposed	219 / 8569 (2.56%)	194 / 8574 (2.26%)	
occurrences causally related to treatment / all	3 / 246	2 / 212	
deaths causally related to treatment / all	1 / 21	0 / 10	
Pneumonia bacterial			
subjects affected / exposed	5 / 8569 (0.06%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia respiratory syncytial viral			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia staphylococcal			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia streptococcal			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	4 / 8569 (0.05%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural cellulitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			

subjects affected / exposed	5 / 8569 (0.06%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative abscess			
subjects affected / exposed	1 / 8569 (0.01%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	13 / 8569 (0.15%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 13	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic abscess			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary sepsis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary tuberculosis			
subjects affected / exposed	3 / 8569 (0.04%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	14 / 8569 (0.16%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	9 / 15	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			

subjects affected / exposed	15 / 8569 (0.18%)	10 / 8574 (0.12%)	
occurrences causally related to treatment / all	5 / 15	3 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis chronic			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Rectal abscess			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal abscess			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	5 / 8569 (0.06%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Retroperitoneal abscess			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rickettsiosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotavirus infection			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonella bacteraemia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal abscess			
subjects affected / exposed	4 / 8569 (0.05%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrub typhus			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	70 / 8569 (0.82%)	77 / 8574 (0.90%)	
occurrences causally related to treatment / all	2 / 71	3 / 84	
deaths causally related to treatment / all	0 / 10	0 / 14	
Sepsis syndrome			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic arthritis staphylococcal			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	24 / 8569 (0.28%)	21 / 8574 (0.24%)	
occurrences causally related to treatment / all	1 / 27	0 / 22	
deaths causally related to treatment / all	0 / 9	0 / 7	
Sinusitis			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis fungal			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin bacterial infection			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue infection			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic abscess			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal abscess			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	3 / 8569 (0.04%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	1 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	5 / 8569 (0.06%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal abscess			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal sepsis			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Streptococcal bacteraemia			
subjects affected / exposed	2 / 8569 (0.02%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tick-borne fever			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth abscess			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth infection			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	2 / 8569 (0.02%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	5 / 8569 (0.06%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			

subjects affected / exposed	67 / 8569 (0.78%)	49 / 8574 (0.57%)	
occurrences causally related to treatment / all	20 / 71	15 / 53	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	1 / 8569 (0.01%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection enterococcal			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	25 / 8569 (0.29%)	22 / 8574 (0.26%)	
occurrences causally related to treatment / all	9 / 26	9 / 23	
deaths causally related to treatment / all	0 / 0	1 / 1	
Vestibular neuronitis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viraemia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	7 / 8569 (0.08%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 8	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral sinusitis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral myocarditis			

subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound abscess			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection pseudomonas			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	10 / 8569 (0.12%)	11 / 8574 (0.13%)	
occurrences causally related to treatment / all	0 / 11	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute hepatitis B			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatitis C			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HIV infection			

subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HIV-associated neurocognitive disorder			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis A			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis B			
subjects affected / exposed	0 / 8569 (0.00%)	2 / 8574 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis E			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
West Nile viral infection			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Adult failure to thrive			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcoholic ketoacidosis			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			

subjects affected / exposed	19 / 8569 (0.22%)	20 / 8574 (0.23%)	
occurrences causally related to treatment / all	1 / 19	1 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	13 / 8569 (0.15%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	1 / 13	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	29 / 8569 (0.34%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	2 / 34	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes with hyperosmolarity			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic complication			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	23 / 8569 (0.27%)	27 / 8574 (0.31%)	
occurrences causally related to treatment / all	2 / 27	2 / 29	
deaths causally related to treatment / all	1 / 2	0 / 0	
Diabetic ketosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic metabolic decompensation			

subjects affected / exposed	27 / 8569 (0.32%)	17 / 8574 (0.20%)	
occurrences causally related to treatment / all	0 / 35	0 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	4 / 8569 (0.05%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Euglycaemic diabetic ketoacidosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	6 / 8569 (0.07%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid retention			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			

subjects affected / exposed	55 / 8569 (0.64%)	37 / 8574 (0.43%)	
occurrences causally related to treatment / all	1 / 56	0 / 49	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	5 / 8569 (0.06%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	6 / 8569 (0.07%)	6 / 8574 (0.07%)	
occurrences causally related to treatment / all	0 / 7	2 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperlipidaemia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypernatraemia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertriglyceridaemia			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperuricaemia			
subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			

subjects affected / exposed	86 / 8569 (1.00%)	69 / 8574 (0.80%)	
occurrences causally related to treatment / all	19 / 101	23 / 86	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypokalaemia			
subjects affected / exposed	4 / 8569 (0.05%)	5 / 8574 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	1 / 8569 (0.01%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	4 / 8569 (0.05%)	14 / 8574 (0.16%)	
occurrences causally related to treatment / all	1 / 4	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	9 / 8569 (0.11%)	9 / 8574 (0.10%)	
occurrences causally related to treatment / all	0 / 9	1 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketoacidosis			
subjects affected / exposed	2 / 8569 (0.02%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 2	2 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lactic acidosis			
subjects affected / exposed	3 / 8569 (0.04%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 3	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Latent autoimmune diabetes in adults			

subjects affected / exposed	1 / 8569 (0.01%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	2 / 8569 (0.02%)	0 / 8574 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipomatosis			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			
subjects affected / exposed	8 / 8569 (0.09%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			
subjects affected / exposed	3 / 8569 (0.04%)	3 / 8574 (0.03%)	
occurrences causally related to treatment / all	1 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 1 diabetes mellitus			
subjects affected / exposed	2 / 8569 (0.02%)	4 / 8574 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	7 / 8569 (0.08%)	7 / 8574 (0.08%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitamin D deficiency			
subjects affected / exposed	0 / 8569 (0.00%)	1 / 8574 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Placebo	Dapa 10 mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	342 / 8569 (3.99%)	268 / 8574 (3.13%)	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	112 / 8569 (1.31%)	82 / 8574 (0.96%)	
occurrences (all)	129	91	
Renal impairment			
subjects affected / exposed	146 / 8569 (1.70%)	121 / 8574 (1.41%)	
occurrences (all)	159	126	
Chronic kidney disease			
subjects affected / exposed	104 / 8569 (1.21%)	77 / 8574 (0.90%)	
occurrences (all)	108	78	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 December 2013	Amendment #2 included implementation of a request from regulatory authorities to include further measurements and action to allow patients to continue study drug if creatinine clearance was found to be <60 ml/min during the study. With these measures added, patients could stay on study drug until creatinine clearance <30 ml/min as planned.
28 April 2014	Amendment #3 included implementation as per regulatory authorities' requirement to add hypersensitivity reactions (SAE/DAE), urinary tract infections (SAE/DAE), genital infections (SAE/DAE) and fractures to be recorded as AE of special interest.
25 September 2016	Amendment #5 included implementation as per regulatory authorities' requirements to add to adjudicate possible cases of diabetes ketoacidosis and collect additional information on cases of amputations.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported